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ABSTRACT
The tumor suppressor Spred2 (Sprouty-related EVH1 domain-2) induces cell
death in a variety of cancers. However, the underlying mechanism remains to be
elucidated. Here we show that Spred2 induces caspase-independent but autophagydependent cell death in human cervical carcinoma HeLa and lung cancer A549 cells.
We demonstrate that ectopic Spred2 increased both the conversion of microtubuleassociated protein 1 light chain 3 (LC3), GFP-LC3 puncta formation and p62/SQSTM1
degradation in A549 and HeLa cells. Conversely, knockdown of Spred2 in tumor cells
inhibited upregulation of autophagosome maturation induced by the autophagy
inducer Rapamycin, which could be reversed by the rescue Spred2. These data
suggest that Spred2 promotes autophagy in tumor cells. Mechanistically, Spred2
co-localized and interacted with LC3 via the LC3-interacting region (LIR) motifs in
its SPR domain. Mutations in the LIR motifs or deletion of the SPR domain impaired
Spred2-mediated autophagosome maturation and tumor cell death, indicating that
functional LIR is required for Spred2 to trigger tumor cell death. Additionally, Spred2
interacted and co-localized with p62/SQSTM1 through its SPR domain. Furthermore,
the co-localization of Spred2, p62 and LAMP2 in HeLa cells indicates that p62 may
be involved in Spred2-mediated autophagosome maturation. Inhibition of autophagy
using the lysosomal inhibitor chloroquine, reduced Spred2-mediated HeLa cell death.
Silencing the expression of autophagy-related genes ATG5, LC3 or p62 in HeLa and
A549 cells gave similar results, suggesting that autophagy is required for Spred2induced tumor cell death. Collectively, these data indicate that Spred2 induces tumor
cell death in an autophagy-dependent manner.

INTRODUCTION

Spreds (Spred1, 2 and 3) contain an N-terminal Ena/VASP
homology 1 domain (EVH1), a central c-Kit binding
domain (KBD) and a C-terminal cysteine-rich Sproutyrelated domain (SPR) that is shared with the Sprouty
proteins [1, 4]. Several studies, including our previous
work, have reported that the EVH1 and SPR domains

Sprouty-related EVH1 domain (Spred) proteins
function as negative regulators of growth factors, cytokines
and chemokine-induced ERK (extracellular-regulated
kinase) activation by binding to Ras and Raf-1 [1–3].
www.impactjournals.com/oncotarget
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play critical roles in the Spred-mediated inhibitory effect
on ERK activation [1, 3, 5–9], although the KBD region
is dispensable [4]. Accumulating evidence indicates that
Spreds function as a tumor suppressor in tumor development
and progression [10–14]. Expression of Spred1 and/or
Spred2 was frequently reduced in hepatocellular carcinoma
and prostate cancer [15, 16], while decreased Spred
levels were associated with increased tumor invasion and
metastasis [16, 17]. Moreover, in vitro and in vivo models
ectopically expressing Spreds led to a decrease in cancer
cell proliferation. This may be due to reduced ERK/MAPK
activity [2, 16]. The underlying mechanism by which
Spreds suppress tumor growth remains to be elucidated.
Macroautophagy (hereafter referred to as autophagy)
is a conserved homeostatic mechanism of lysosomal
degradation. The hallmark of autophagy is the formation
of double- or multi-membrane vesicles in the cytosol called
autophagosomes that encapsulate bulk cytoplasm and
cytoplasmic organelles. These autophagosomes mature
by fusing with the endocytic compartments (e.g. early and
late endosomes, multivesicular bodies) and then fusing
with the lysosomal compartment to form autolysosomes,
in which the cargo is degraded by acidic lysosomal
hydrolases [18, 19]. The process is tightly regulated by a
set of core autophagy-related (ATG) proteins, including
the ubiquitin-like modifier, ATG8. During autophagy,
the microtubule-associated protein 1 light chain 3 (LC3),
which is the mammalian homologue of yeast ATG8, is
converted to lipidated LC3 II and associates with the
autophagic membrane. The accumulation of LC3 II and its
localization to the autophagosome (puncta dot formation)
are generally used as markers for autophagy [20]. Lipidated
LC3 II recruits receptors for specific cargo, such as p62
(also known as SQSTM1) [21], neighbor of BRCA1
(NBR1) [22–24] and adaptor proteins that modulate the
movement and maturation of autophagosomes [25, 26]. All
known autophagy receptor and adaptor proteins contain
one or more LC3-interacting region (LIR) motif(s) with
the consensus hydrophobic sequence W/Y/F-X-X-I/L/V
[21, 27]. Recent studies have shown that several tumor
suppressors, such as p53 and PTEN, may induce autophagydependent cell death in tumor cells [28, 29], suggesting that
autophagy modulation could be a critical mechanism for
tumor suppression.
We previously reported that tyrosines 303/343/353
at the SPR domain is essential for Spred2-mediated
inhibition of tumor cell growth [8]. In this study, we
show that Spred2 induces autophagy-associated tumor
cell death by increasing autophagosome maturation. We
further demonstrate that Spred2 enhances autophagosomelysosome fusion by binding to LC3 via two LIR motifs
at the SPR domain. Importantly, both the functional LIR
and Spred2-associated autophagy are required for Spred2
to induce tumor cell death. Taken together, our study
provides new insights into the underlying mechanisms by
which Spred2 induces tumor cell death.
www.impactjournals.com/oncotarget

Spred2 induces autophagy-associated tumor cell
death
Using clone formation assays, we showed that
infection with adenoviruses expressing Myc-tagged
Spred2 (Ad-Spred2) results in the significant inhibition
of colony formation in HeLa and A549 cells compared
to control virus (Figure 1A), consistent with our previous
work and others that Spred2 suppresses tumor cell growth
[2, 8, 16]. To investigate whether apoptosis is involved
in Spred2-induced tumor cell growth inhibition, HeLa
cells infected with Ad-Spred2 were analyzed by flow
cytometry using Annexin V and propidium iodide (PI)
double-staining. Relative to control virus, Ad-Spred2
infection increased the fraction of cells staining with
Annexin V and PI at 24, 48 and 72 h, suggesting that
Spred2 may induce apoptosis in these cells (Figure 1B).
However, activation of Caspase-3 (effector of apoptosis)
and cleavage of PARP (downstream target of active
caspase-3) were not observed in Spred2-overexpressing
HeLa cells as detected by immunoblotting (Figure 1C).
As a positive control, Doxorubicin treatment induced
marked cleavage of Caspase-3 and PARP (Figure 1C).
Similar results were obtained in A549 cells (Figure S1A).
Spred2 levels were modestly overexpressed in these lines
by approximately 8-fold relative to the endogenous basal
levels (Figure 1C and Figure S1A). Furthermore, Spred2induced HeLa cell death was not blocked by pre-treatment
with the broad-specificity caspase inhibitor, Z-VAD-FMK
(Figure 1D), which inhibited Doxorubicin-induced apoptosis
(Figure S1B). This would suggest that Spred2-induced cell
death may not be caspase-dependent.
Given that autophagy plays a role in cell death
triggered by tumor suppressors [28, 29], we hypothesized
that Spred2 induces autophagy-associated cell death. To test
this, we first examined whether Spred2 induces autophagy in
tumor cells. Ultrastructural analysis by transmission electron
microscope detected several degradative autophosomes in
Ad-Spred2-infected HeLa cells which were rarely observed
in HeLa cells infected with control virus (Figure 1E, arrow
indicated). To confirm that the observed double-membraned
vesicles were indeed related to autophagy, GFP-LC3 dot
formation was investigated. Upon autophagy, LC3 is
localized on autophagosomes and LC3 puncta are used
as a marker for autophagosomes [30]. HeLa cells were
co-transfected with GFP-LC3 and Myc-Spred2 or vector
control. As depicted in Figure 1F, the number of cells with
GFP-LC3 puncta in Spred2-overexpressing HeLa cells
was higher than in control cells. Bafilomycin A1 (BafA1)
is a specific inhibitor of the vacuolar type H+-ATPase
(V-ATPase). This is known to block autophagosomelysosome fusion [31], leading to the accumulation of
autophagic vacuoles, as demonstrated by a marked
accumulation of LC3II. We observed that BafA1 treatment
25653
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further increased the number of cells with GFP-LC3
puncta in Spred2-overexpressing HeLa cells (Figure 1F).
Similar results were observed in HeLa cells treated with
Rapamycin (Rapa), which selectively inhibits mTOR
to simulate autophagy (Figure 1F) [30]. The autophagic
substrate, p62, which is specifically degraded by the
autophagic-lysosomal pathway, was widely used to monitor
autophagy flux [32]. Unlike the control cells, in cells with
suppressed autophagosome maturation (i.e., BafA1 treated
cells) the loss of p62 upon treatment with Ad-Spred2
was not apparent in HeLa and A549 cells (Figure 1G).
This BafA1-dependent loss of p62 in response to Spred2
indicates that exogenous Spred2 may activate the formation
of autophagosomes rather than suppress their maturation.
To examine whether the autophagy induced by
Spred2 serves as a pro-survival or pro-death mechanism,
lentivirus expressing shRNA targeting ATG5 were used to
stably knock down ATG5 in HeLa and A549 cells (HeLa/
shATG5 and A549/shATG5). Atg5 is a key molecule
involved in autophagic vacuole formation, and the
formation of the Atg12-Atg5 conjugate is indispensable
to autophagosome formation. [33–35] So the autophagy
process was blocked in ATG5-knockdown cells.
Lentiviruses with control shRNA were used to establish the
control cell lines (HeLa/shControl and A549/shControl).
These cell lines were then infected with AdSpred2 and
were analyzed by trypan blue dye exclusion. Spred2triggered cell death was reduced in HeLa/shATG5 cells
compared with HeLa/shControl cells (Figure 1H). This
observation was further confirmed by Annexin V and PI
double-staining by flow cytometry (Figure 1I). Similar
results were obtained in A549/shATG5 cells (Figure S1C
and S1D). Depletion of ATG5 in HeLa and A549 cells was
confirmed by immunoblotting (Figure 1J and Figure S1E).
Consistently, pharmacological inhibition of autophagy by
pretreatment with chloroquine (CQ), an autophagolysosome
fusion inhibitor [30], attenuated Spred2-induced cell death
in HeLa cells (Figure 1K). Together, these data indicate that
inhibition of autophagy attenuates Spred2-mediated cell
death in tumor cells.

An increase in red-only dot was observed in HeLa cells
transfected with Myc-Spred2 (Figure 2A). Moreover, in
Spred2-overexpressing cells, treatment with Rapa resulted
in a further increase in both yellow and red-only dot,
whereas BafA1 treatment led to an increase in yellow
dot and decrease in red-only dot (Figure 2A and 2B). In
addition, we observed that BafA1-only or Rapa-only
treatment increased the number of yellow dot in control
HeLa cells (Figure 2A and 2B). As expected, treatment with
Rapa induced an increase in the number of red-only dot in
control HeLa cells (Figure 2A and 2B). These data suggest
that overexpression of Spred2 enhances autophagosome
maturation in HeLa cells.
To further establish the role of Spred2 in
autophagosome maturation, Spred2 was knocked down by
siRNA in HeLa cells and the efficiency was confirmed by
immunoblotting (Figure 2C). To rule out the possibility of
off-target effects, two independent siRNA oligonucleotides
were used, both of which gave similar results. We observed
the accumulation of both LC3 II and p62 in Spred2knockdown HeLa cells but not in control cells transfected
with non-target siRNA, suggesting that Spred2 knockdown
impaired autophagic degradation (Figure 2C and 2D). In
addition, the effect of Spred2 knockdown on LC3 II and p62
levels was rescued by expressing a Spred2 rescue plasmid
(Figure 2C and 2D). We also found that Spred2 knockdown
could inhibit the upregulation of autophagosome maturation
induced by Rapa, which was reversed by the rescue Spred2
expression plasmid (Figure 2E and 2F). This observation
would indicate that Spred2 knockdown disrupted
autophagosome maturation in cancer cells. Of note, loss of
endogenous Spred2 abolished the ability of rapamycin to
suppress p62 levels in HeLa cells (Figure 2G), suggesting
that Spred2 promotes autophagosomes maturation. Above
all, the effect of the autophagy modulators and Spred2 are
shown in Table S2.

Spred2 co-localizes with autophagic organelles
The above findings that Spred2 enhances the
autophagic process prompted us to explore how Spred2
interacts with the autophagy machinery. We examined
whether Spred2 co-localizes with autophagic organelles.
ATG16L1 has been used to monitor the movement of plasma
membrane as a donor for autophagy, and ATG16L1 is
located on phagophores, but not completed autophagosomes.
[37, 38] No co-localization was observed between Myctagged or endogenous Spred2 and endogenous ATG16L1
in COS7 or HeLa cells. Similarly, CQ did not promote this
co-localization (Figure S2A and S2B). However, confocal
microscopy analysis revealed substantial co-localization of
endogenous Spred2 and GFP-LC3 in cytoplasmic puncta in
HeLa cells (Figure 3A). In addition, a similar co-localization
of Myc-Spred2 with GFP-LC3 was also observed in HeLa
cells (Figure 3B), indicating that Spred2 co-localizes with
LC3. We also observed co-localization between Myc-Spred2
and endogenous LAMP2 in HeLa cells (Figure 3C), a late

Spred2 promotes autophagosome maturation in
cancer cells
To elucidate the role of Spred2 in enhancing the
autophagic process, we utilized a tandem fluorescent GFPmRFP-LC3 marker to analyze autophagosome maturation
[36]. In this system, autophagosomes display both green
and red fluorescence, while autolysosomes display
only red fluorescence as the GFP loses its fluorescence
from deprotonation in the acidic lysosomes. Therefore,
autophagosomes appear as RFP+GFP+ (yellow dot) and
mature, autolysosomal organelles appear as RFP+GFP(red-only dot). Thus, autophagosome maturation can be
indicated by a dramatic increase in the number of red-only
autolysosomes [36]. HeLa cells were co-transfected with
GFP-mRFP-LC3 and Myc-Spred2-WT or vector control.
www.impactjournals.com/oncotarget
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Figure 1: Spred2 triggers autophagy-associated tumor cell death. Cells were infected with adenoviruses expressing Myc-

Spred2-WT (AdSpred2-WT) or vector control (Ad-Vector) at a multiplicity of infection of 250 for 8 h (A, B, C, E). (A) HeLa and
A549 cells were cultured in complete medium for 12 days during colony formation assays. (B) After 24, 48 or 72 h, HeLa cells were
double stained with annexin V (AV) and propidium iodide (PI) for flow cytometric analysis (FACS). (C) Cell lysates were analyzed by
immunoblotting with anti-Caspase-3, anti-PARP, anti-Spred2 and anti-GAPDH. Doxrubicin was used as a positive control. (D) HeLa cells
were infected with AdSpred2-WT or Ad-Vector in the presence or absence of pan-caspase inhibitor (50 μM Z-VAD-FMK, Pan) for 24,
48 and 72 h by FACS. (E) HeLa cells were examined by transmission electron microscopy (TEM). a, Untreated control HeLa cells showing
normal distribution of organelles; b, HeLa cells infected with adenoviruses expressing Spred2. In the lower panels, typical structures
enclosed in the black square have been enlarged for more detailed imaging; c, the degradation of the engulfed rough ER is advanced in
this degradative autophagosome (indicated by black arrow); d, cup-shaped membranous structures and vacuoles present in the cytoplasm
(indicated by black arrows). (F) HeLa cells were co-transfected with GFP-LC3 and vector or Myc-Spred2. These were then treated with
Rapa (1 μM) or BafA1 (50 μM) for 4 or 24 h. The number of cells with GFP-LC3 punctate are represented. (G) HeLa and A549 cells
were infected with Ad-vector or Ad-Spred2 and treated with BafA1 (50 μM). Cell lysates were analyzed by immunoblotting for LC3, p62,
Spred2 and GAPDH protein expression. Hela/shControl or HeLa/shATG5 cells were infected with Ad-Vector or AdSpred2-WT as indicated
for 8 h (H, I). (H) After 24, 48 and 72 h, cell death was determined using the trypan blue assay. (I) Cell death was determined by AV/PI
double staining analysis. (J) Cell lysates from HeLa/shControl and HeLa/shATG5cells were analyzed by IB to determine the efficiency of
ATG5 knockdown. (K) HeLa cells pre-treated with CQ were infected with Ad-Vector or AdSpred2-WT as indicated for 8 h. After 24, 48 and
72 h, cell death was determined using the trypan blue assay. Data are represented as the mean ± S.D from three independent experiments
(**p < 0.01, ***p < 0.001).
www.impactjournals.com/oncotarget
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Figure 2: Spred2 enhances autophagosome maturation. (A) HeLa cells were co-transfected with GFP-mRFP-LC3 and vector

or Myc-Spred2 and treated with or without Rapa (1 μM) or BafA1 (50 μM). Images were acquired by confocal microscope. The merged
region enclosed within the white square has been enlarged in the right panel for clearer appreciation of these co-localizations. (B) The
number of autophagosomes (yellow dots) and autolysosomes (red-only dots) per cell were quantified. HeLa cells were transfected with
two siRNA duplexes targeted to Spred2 (siSpred2) or control siRNA (siControl) for 48 h (C, D, E, F,). (C) Cells were transfected with
vector control or a Spred2 rescue plasmid (Rescue-Spred2). After 24 h, cell lysates were analyzed by immunoblotting for Spred2, LC3,
p62 and β-actin protein expression. (D) The ratios of expression for each protein to their corresponding β-Actin are represented. (E) Cells
were co-transfected with GFP-mRFP-LC3 and vector control or a Spred2 rescue plasmid for 24 h following Rapa-treatment for 4 h.
Images were acquired by confocal microscopy. The merged region enclosed within the white square has been enlarged in the right panel
for clearer appreciation of these co-localizations. Scale bars are representative of 50 μm. (F) The number of autophagosomes (yellow dots)
and autolysosomes (red-only dots) per cell were quantified. (G) HeLa cells were transfected with two siRNA duplexes targeted to Spred2
(siSpred2) or control siRNA (siControl) for 72 h. Cells were treated with or without Rapa (1 μM) for 4 h. Cell lysates were analyzed by
immunoblotting for Spred2, LC3, p62 and β-Actin protein expression. The ratios of each specific protein to their corresponding β-Actin
are represented. All quantitative data are represented as the mean ± S.D from three independent experiments (**p < 0.01, ***p < 0.001).
www.impactjournals.com/oncotarget
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Spred2 binds to LC3 via the LIR motifs in the
SPR domain

endosomal/lysosomal marker that co-localizes with LC3
during autophagsosome maturation [39]. These data indicate
that Spred2 co-localizes with autophagic organelles.
To examine the degree of overlap of Myc-Spred2 and
GFP-LC3, each image from three distinct areas (regions
of interest, ROIs) were sampled to correct background.
Manders’ overlap coefﬁcient (R) was employed to evaluate
co-localization. An average of coefﬁcients obtained
from the examined ﬁeld was calculated. Rapa treatment
increased Myc-Spred2 and GFP-LC3 overlap, whereas
treatment with CQ induced co-localization of Spred2 and
LC3 on autophagic structures (Figure 3B). Similar results
were obtained in COS7 cells (Figure S2C and S2D). These
would suggest that the co-localization of Myc-Spred2 and
GFP-LC3 were increased by autophagy modulators.

The observation of co-localization of Spred2
with LC3 in autophagic organelles led us to speculate
whether Spred2 binding to LC3. Endogenous Spred2 and
endogenous LC3 were reciprocally immunoprecipitated in
HeLa cells (Figure 4A and 4B). The interaction between
Spred2 and LC3 was further demonstrated to be direct
by in vitro pull-down assays with recombinant proteins
(Figure 4C), supporting the existence of a Spred2-LC3
interaction at physiological protein levels.
To determine which domain of Spred2 is responsible
for this binding, a series of Myc-tagged truncation
constructs of Spred2, named Spred2-ΔEVH1, Spred2-

Figure 3: Spred2 localizes with LC3-positive autophagic structures. Cells were fixed and analyzed for co-localization by

confocal microscopy. The merged region enclosed within the white square has been enlarged in the right panel for a clearer appreciation of
the co-localizations. (A) HeLa cells overexpressing GFP-LC3 were analyzed for endogenous Spred2/GFP-LC3 co-localization. Scale bars
are representative of 10 μm. (B) HeLa cells co-transfected with Myc-Spred2 and GFP-LC3 were treated with rapamycin (Rapa, 1 μM), CQ
(50 μM), or vehicle control for 4 h. Cells were analyzed for Myc-Spred2/GFP-LC3 co-localization. The percentage of co-localization was
quantified. Data are represented as mean ± S.D from three independent experiments (**p < 0.01). (C) Myc-Spred2/LAMP2 co-localization
in HeLa cells overexpressing Myc-Spred2. Green staining, Myc-Spred2; red, total endogenous LAMP2 and blue staining for the cell
nucleus. Scale bars are representative of 25 μm.
www.impactjournals.com/oncotarget

25657

Oncotarget

ΔKBD and Spred2-ΔSPR (Figure 4D), were prepared and
used in co-immunoprecipitation (co-IP) assays. Further
motif mapping revealed two potential LIR motifs in the
SPR domain; W370XXL373and Y386XXL389 (Figure 4E).
GFP-LC3 could be immunoprecipitated with Myc-Spred2
in transfected 293T cells while the SPR domain of Spred2
was the only LC3 binding region (Figure 4F). To determine
whether these two LIR sequences in the SPR domain are
required for Spred2 binding to LC3, W370, Y386, L373
and L389 were all mutated to alanine (A). The resulting
constructs were named as Spred2-W370A/L373A and
Spred2-Y386A/L389A,
respectively.
Surprisingly,
mutating either W370/L373 or Y386/L389 alone did not
abolish Spred2 binding to LC3. However, four mutations
of W370/L373 and Y386/L389 (Spred2- W370A/L373A/
Y386A/L389A, shown here as Spred2-AA), completely
abrogated LC3 binding to Spred2 (Figure 4G). Similar data

was observed in pull-down experiments by Myc-Spred2AA with GST-LC3 (Figure 4C), indicating that either LIR
sequence in the SPR domain is sufficient for Spred2 binding
to LC3.

LIR motifs are required for Spred2-activated
autophagosome-lysosome fusion
Next, we evaluated whether Spred2 binding to LC3
is essential for its ability to promote autophagosomelysosome fusion. HeLa cells overexpressing Spred2WT, Spred2-ΔSPR, Spred2-AA or vector control with
the tandem fluorescent GFP-mRFP-LC3 were examined
for the level of autophagosome-lysosome fusion. Spred2
overexpression increased the amount of red-only dot
representing autolysosomes compared with vector control
(Figure 5A). However, there was no change in the amount

Figure 4: Functional LIR motifs in the SPR domain mediate Spred2/LC3 interaction. (A) HeLa whole-cell lysates (WCL)

collected from 10 cm2 dishes were subjected to immunoprecipitation (IP) with an anti-LC3 antibody or an IgG control. (B) HeLa whole-cell
lysates collected as A were subjected to IP using an anti-Spred2 antibody or an IgG control. (C) GST pull-down assays to analyze binding
of an in vitro translated Myc-Spred2-WT or Myc-Spred2-AA (upper panel) against recombinant human GST-LC3 protein. The purified
GST-alone and GST-LC3 protein used are displayed on the Coomassie-stained gels (bottom panel). (D) Schematic representation of the
Spred2 domains. A series of Myc-tagged truncation constructs of Spred2 were named Spred2-ΔEVH1, Spred2-ΔKBD and Spred2-ΔSPR.
(E) Sequence alignment of mutations in the SPR domain containing the LC3-interaction region (LIR) motifs (W370XXL373and Y386XXL389).
Both tryptophan 370/leucine 373 and tyrosine 386/leucine 389 were mutated to Alanine and the resulting plasmids were subsequently
named as Spred2-W370A/L373A and Spred2-Y386A/L389A, respectively. A four mutation of W370/L373 and Y386/L389 was created
and named Spred2-W370A/L373A/Y386A/L389A, shown here as Spred2-AA. (F) 293T cells were co-transfected with GFP-LC3 and
Myc-Spred2-WT or various Spred2 deletion constructs. (G) 293T cells were co-transfected with GFP-LC3 and Myc-Spred2-WT or Spred2
mutants. (F, G) Whole-cell lysates (WCL) were IP with an anti-Myc antibody and proteins were resolved by IB. All experiments in this
figure were performed as three independent experiments.
www.impactjournals.com/oncotarget
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of red-only dot in cells overexpressing Spred2-ΔSPR or
Spred2-AA. Similar results were observed in A549 cells
(Figure 5B). Together, these findings indicate that the
LIR motifs in the SPR domain are essential for Spred2activated autophagosome-lysosome fusion.

(Figure 6B and Figure S3A). Furthermore, the binding
of Spred2 with p62 in vivo was dependent on the SPR
domain (Figure 6C), which was confirmed by colocalization experiments (Figure S3B). Notably, Spred2AA mutant was able to bind and co-localize with p62
in HeLa cells (Figures 6D and S3B). Interestingly, we
observed co-localization among GFP-Spred2, endogenous
p62 and endogenous LAMP2 in HeLa cells (Figure 6E).
The co-localization of Myc-Spred2 and endogenous p62
in HeLa cells was also observed (Figure 6F). This overlap
was decreased by CQ or BafA1 (Figure 6F). However,
the effect of Rapa on Spred2 and p62 co-localization was
minimal (Figure 6F). These data indicate that Spred2
interacts and co-localizes with p62 during the fusion
of autophagosomes with lysosomes, a process that is
sensitive to CQ and BafA1 treatment.

Spred2 interacts and co-localizes with p62
Previously, Heath and colleagues found that MycSpred2 interacts with endogenous p62 in 293T cells [9].
Given that Spred2 promotes autolysosome formation, we
examined whether p62 is involved in Spred2-mediated
autolysosome formation. Endogenous p62 could be
immunoprecipitated with endogenous Spred2 in HeLa
cells (Figure 6A). In addition, Myc-Spred2 and Flag-p62
were reciprocally immunoprecipitated in 293T cells

Figure 5: LIR motifs are required for Spred2-mediated autophagosome-lysosome fusion. (A, B) HeLa cells (A) or A549

cells (B) were co-transfected with vector, Myc-Spred2-WT, Myc-Spred2-ΔSPR or Myc-Spred2-AA and GFP-mRFP-LC3. Images of live
cells were captured by confocal microscopy and the number of autophagosomes (yellow dots) and autolysosomes (red-only dots) per cell
were quantified. The merged region enclosed in the white square has been enlarged on the right panel for a clearer appreciation of these
co-localizations. Scale bars are representative of 50 or 25 μm. Data are represented as mean ± S.D from three independent experiments
(***p < 0.001).
www.impactjournals.com/oncotarget
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LC3 contributes to the interaction and
co-localization of Spred2 with p62

the binding of Spred2 with p62 during autolysosome
formation. To test this hypothesis, Myc-Spred2 and
FLAG-p62 were co-transfected in 293T cells with a
stable depletion of LC3. Compared with control 293T
cells, the binding of Spred2 with p62 was reduced in
LC3-knockdown cells, as assayed by co-IP (Figure 7A).

Based on our findings that LC3 is essential
for Spred2-mediated promotion on autophagosome
maturation, we hypothesized that LC3 is necessary for

Figure 6: Spred2 interacts and co-localizes with p62. (A) HeLa whole-cell lysates collected from 10 cm2 dishes were subjected

to IP with an anti-Spred2 antibody or an IgG control to detect endogenous Spred2 binding to endogenous p62. (B) 293T cells were cotransfected with FLAG-p62 or vector, in addition to Myc-Spred2-WT or vector. (C) 293T cells were co-transfected with FLAG-p62 and
Myc-Spred2-WT or various Spred2 deletion constructs. WCL were IP with an anti-FLAG antibody. (D) 293T cells were co-transfected
with FLAG-p62 and Myc-Spred2-AA construct. (B, D) Whole-cell lysates (WCL) were IP with an anti-Myc antibody and were resolved by
IB. (E) HeLa cells were transfected with GFP-Spred2. The co-localization of GFP-Spred2, endogenous LAMP2 and endogenous p62 was
detected. The merged region enclosed within the white square has been enlarged in the bottom panel for better appreciation and the arrows
indicate the regions of merge. (F) HeLa cells overexpressing Myc-Spred2 were either untreated or treated with Rapa (1 μM), CQ (50 μM)
or BafA1 (50 μM) for 4 h. Myc-Spred2/endogenous p62 co-localization was detected. The merged region enclosed within the white square
has been enlarged in the right panel for clearer appreciation and the arrows indicate the regions of merge. Scale bars are representative of
25 μm. All experiments in this figure were performed as three independent experiments.
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Consistently, the co-localization of Myc-Spred2 and
endogenous p62 was decreased in HeLa cells with a
stable depletion of LC3 compared to control cells (Figure
7B). Inducing autophagy with Rapa did not increase the
co-localization of Spred2 and p62 in cells depleted of LC3
(Figure 7B). LC3 protein expression in HeLa cells was
determined by immunoblotting (Figure 7C). These results
suggest that LC3 is essential for Spred2 interaction and
co-localization with p62.

induced autophagy-associated cell death. HeLa cells were
infected with adenoviruses expressing Myc-Spred2-WT,
Myc-Spred2-ΔSPR, Myc-Spred2-AA (LC3 mutated
binding sites) or an empty vector control. The cells were
then subjected to either a clone formation assay or trypan
blue dye exclusion analysis. AdSpred2 infection resulted in
the formation of fewer colonies and more dead cells relative
to the control virus, AdSpred2-ΔSPR and AdSpred2AA (Figure 8A and 8B), indicating a role of the LIR in
Spred2-induced cancer cell death. The protein levels of
these adenoviruses were validated by immunoblot analysis
(Figure 8B). To further assess the extent to which the
observed cell death depends on autophagy, trypan blue dye
exclusion experiments were performed in LC3-knockdown
or p62-knockdown HeLa and control cells, infected
with AdSpred2 or control virus, respectively. Following
AdSpred2 infection, fewer dead cells were detected in

Abolishment of the association of Spred2 with
LC3 and depletion of LC3 or p62 impedes
Spred2-mediated tumor cell death
Given that Spred2 interacts with LC3 and contributes
to Spred2-mediated autophagy, we investigated whether the
interaction between Spred2 and LC3 is essential for Spred2-

Figure 7: LC3 is essential for Spred2 interaction and co-localization with p62. (A) 293T cells with a stable knockdown of LC3

(293T/shLC3) and control cells (293T/shControl) were co-transfected with Myc-Spred2 and FLAG-p62. Whole-cell lysates (WCL) were
IP with anti-Myc and resolved by IB. LC3 and GAPDH protein expression in response to LC3 knockdown was determined. (B) HeLa cells
with a stable knockdown of LC3 (HeLa/shLC3) and control (HeLa/shControl) cells were transfected with Myc-Spred2 and treated with
Rapa (1 μM) for 4 h. The co-localization of Myc-Spred2 and endogenous p62 was detected. The merged region enclosed within the white
square has been enlarged in the right panel for clearer appreciation and the arrows indicate the regions of merge. Scale bars are represented
as 25 μm. (C) Cell lysates of HeLa/shLC3 cells and HeLa/shControl cells were analyzed by IB to determine the efficiency of the LC3
knockdown. All experiments in this figure were performed as three independent experiments.
www.impactjournals.com/oncotarget

25661

Oncotarget

p62-knockdown or LC3-knockdown HeLa cells than
in control cells (Figure 8C and 8D). We observed
similar results in p62-knockdown or LC3-knockdown
A549 cells (Figure S4A and S4B). The efficiency of LC3
or p62 knockdown in HeLa and A549 cells was examined

respectively by immunoblotting (Figures 8E, 8F, S4C
and S4D). Both LC3 and p62 were essential for Spred2mediated cell death. Together, these data along with results
from Figure 1H and Figure 1I, suggest that autophagy
contributes to Spred2- induced tumor cell death.

Figure 8: Abolishing the association of Spred2 with LC3 and depletion of LC3 or p62 impedes Spred2-mediated tumor
cell death. (A, B) Cells were infected with adenoviruses expressing Myc-Spred2-WT (AdSpred2-WT), Myc-Spred2-ΔSPR (AdSpred2ΔSPR), Myc-Spred2-AA (AdSpred2-AA) or vector control (Ad-Vector) at a multiplicity of infection of 250 for 8 h. (A) HeLa cells were
cultured in complete medium for 12 days during colony formation assays. The graph represents the number of colonies present in the plate
at the end of this time. (B) Cell death was determined by cell counting using trypan blue exclusion staining of HeLa cells. Expression
in response to the overexpression of constructs was also examined by IB. (C, D) Cells with a stable knockdown of LC3 (HeLa/shLC3),
p62 (HeLa/shp62) or control cells (HeLa/shControl) were infected with adenoviruses expressing Myc-Spred2-WT or vector control at a
multiplicity of infection of 250 for 8 h. HeLa/shControl or HeLa/shLC3 cells (C) and HeLa/shControl or HeLa/shp62 (D) were determined
by cell counting using trypan blue exclusion staining for cell death analysis. (E, F) Cell lysates of HeLa/shLC3 cells or HeLa/shControl
cells (E) and HeLa/shp62 cells or HeLa/shControl cells (F) were analyzed by IB to determine the efficiency of LC3 or p62 knockdown. Data
are represented as mean ± S.D from three independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001).
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DISCUSSION

in hepatocellular carcinoma and prostate cancer [15, 16],
while forced Spred2 expression suppresses cell growth in
a variety of tumor cells [15–17]. We recently reported that
forced expression of Spred2 inhibits HeLa cell growth while
deletion of the SPR domain attenuates this inhibitory effect
[8]. In the present study, we show that Spred2-associated
autophagy can induce tumor cell death. This notion was
further supported by our observation that Spred2-mediated
tumor cell death was impaired by either mutations in the
LIR motifs in Spred2 or knockdown of ATG5, LC3 or
p62. Several reports have shown that tumor suppressors
trigger autophagy-dependent cell death [28, 29, 40].
In a study by Seillier et al, the tumor suppressor protein
53-induced nuclear protein 1 (TP53INP1), was shown to
bind to LC3 through the LIR and promotes autophagydependent tumor cell death [40]. The tumor suppressor
p53 also induces autophagic cell death in cancer cells [41].
These data together with our findings, suggest that the
autophagy process promoted by tumor suppressors, may be
a mechanism in tumor suppression.
Taken together, this study demonstrates that
through its interaction with LC3, Spred2 enhances
autophagosome maturation thereby contributing to tumor
cell death. Our study also suggests that autophagy may
be a potential target for enhancing Spred2-mediated antitumor activity.

Collectively, our results indicate that Spred2 triggers
tumor cell death in an autophagy-dependent manner. We
demonstrate that Spred2 induces autophagy and enhances
autophagosome maturation in tumor cells. Mechanistically,
Spred2 interacts and co-localizes with LC3 via the LIR
motifs in the SPR domain, while the functional LIR motifs
mediate Spred2-associated autophagosome maturation and
contribute to Spred2-induced tumor cell death. In addition,
Spred2 interacts and co-localizes with p62 and depletion
of p62 in tumor cells, attenuating Spred2-triggered cell
death. Together, our data uncover a novel mechanism by
which Spred2 exhibits its tumor suppressor function.
To our knowledge, this is the first report showing
that autophagy is involved in Spreds-mediated tumor
cell death. Our results demonstrated that Spred2, a
tumor suppressor, enhances the autophagic process in
cancer cells by increasing autophagosome maturation.
Furthermore, knockdown of Spred2 impairs the autophagy
flux and the autophagy inducer Rapamycin, has no effect
on Spred2 knockdown-induced p62 accumulation in
cancer cells. These observations indicate that endogenous
Spred2 promotes autophagic degradation. Moreover,
pharmacological inhibition of autophagy and knockdown of
the key autophagy-related genes decreases Spred2-induced
cancer cell death, indicating that Spred2 triggers cancer cell
death in an autophagy-dependent manner.
We also provide insights into the molecular
mechanism by which Spred2 enhances autophagosome
maturation. Specifically, our results underline the
importance of the interaction of Spred2 with LC3 via the
two LIR motifs in the SPR domain. Mutations in the LIR
motifs decreased the number of red-only autolysosomes,
thereby impairing the autophagosome-lysosome fusion.
Previous studies have reported an interaction between
Spred2 and p62 [9]. We further demonstrate that the SPR
domain mediates the binding and co-localization of Spred2
with p62. Consistent with previous findings by Mardakheh
et al. [9], we observed that Myc-tagged-Spred2-ΔSPR
was mainly localized in the nucleus of cancer cells, while
the majority of myc-Spred2 in these cells exhibited a
puncta cytoplasmic staining. It is possible that the nuclear
localization of Spred2-ΔSPR is either the reason or the
consequence of the lacking interaction with autophagosome
components. Notably, we found that Spred2 interaction and
co-localization with p62 is dependent on the Spred2/LC3
interaction. Spred2 is also shown to interact with NBR1
and of interest, co-localizes with NBR1 and p62 [9]. Both
NBR1 and p62 are selective autophagy substrates and
receptors that bind to LC3 via their LIR motifs. Based on
our observations that Spred2 interacts and co-localizes with
LC3 and p62, our data suggest that Spred2 is a scaffold
protein in autophagosome maturation.
Spred2 functions as a tumor suppressor in a variety
of cancers. Decreased expression of Spred2 is observed
www.impactjournals.com/oncotarget

MATERIALS AND METHODS
Cell culture and transfection
Human embryonic kidney cells (293T), monkey
fibroblast-like kidney cells (COS7), human cervical
carcinoma cells (HeLa) and human lung cancer cells (A549)
were purchased from American Type Culture Collection
(ATCC). 293T, COS7 and A549 cell lines were cultured
in DMEM (Gibco) supplemented with 10% fetal bovine
serum (FBS) and HeLa cells were cultured in MEM (Gibco)
supplemented with 10% FBS. All cells were cultured in a
humidified incubator under 5% CO2 at 37°C. Transfection
of plasmids into all cells (for immunoprecipitation or
immunofluorescence) was performed using Lipofectamine
2000 (Invitrogen), according to the manufacturer’s
instructions.

Antibodies and reagents
For a list of antibodies, see Table S1. Bafilomycin
A1 (BafA1) was purchased from Merck Millipore.
Doxorubicin (Dox), Chloroquine (CQ) and Rapamycin
(Rapa) were purchased from Sigma and diluted in
dimethyl sulfoxide (DMSO). The caspase inhibitor
Z-VAD-FMK (Pan) was purchased from Selleckchem.
Small interfering RNA (siRNA) against Spred2 and
non-targeting siRNA controls were obtained from
Qiagen.
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Immunoprecipitation and immunoblotting

cell populations were subjected to immunoblotting to
investigate the silencing efficiency.

Immunoprecipitation (IP) and immunoblotting (IB)
were performed as previously described [42]. In some
cases, membranes were stripped and re-probed with
specific antibodies. To quantify changes, the densitometries
of protein bands were determined with a calibrated GS670 densitometer. For endogenous interactions, HeLa cells
grown in 10 cm2 dishes were harvested and the cell lysates
were then subjected to IP. All IP and IB experiments were
performed as three independent experiments.

RNA interference
RNA interference was used to knock down targeted
proteins of interest. Two siRNA oligonucleotides were
used for Spred2: 5′-AAGGACTTGGTCTACACCAAA-3′
and 5′-CAGACCCTTGCTCGTGCGATA-3′. Transfection
of siRNA was performed as previously described [42]. A
scrambled siRNA was used as a negative control and the
silencing efficiency was detected by immunoblot analysis.
A Myc-tagged Spred2 rescue plasmid was generated by
creating three silent base-pair mutations in the wild type
sequence [44].

GST-pull down assays
GST-tagged-LC3 protein was expressed in
Escherichia coli SoluBL21. Expression was induced by
addition of 0.5 mM IPTG and cells were incubated at 20°C
overnight. Collected cells were lysed using sonication
in buffer (20 mM Tris-HCl at pH 7.5, 10 mM EDTA,
5 mM EGTA and 150 mM NaCl). GST fusion protein
was purified on glutathione-Sepharose 4 Fast Flow beads
(GE Healthcare). For GST pull-down using cell lysates,
293T cells were transfected with Myc-Spred2 using
transfection reagent (Lipofectamine 2000, Invitrogen). Cells
were lysed and were incubated with GST-LC3 protein on
glutathione-Sepharose beads in binding buffer (50 mM
Tris, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40, pH 8.0,)
supplemented with protease inhibitor for 1 h at 4°C.
Following five washes, the beads and precipitated proteins
were eluted with 5 × SDS-PAGE loading buffer, boiled and
loaded on SDS-PAGE gels for analysis.

Transmission electron microscopy
For ultrastructural analysis, standard transmission
electron microscopy (TEM) was carried out. Adenovirus
infection was performed as above. Four hours after
infection, the cells were ﬁxed and embedded. Thin sections
(90 nm) were cut and examined at 80 kV with a JEOL
1200EX transmission electron microscope. Approximately
15 cells were counted and autophagosomes were deﬁned
as structures measuring 0.5 to 2.0 μm.

Fluorescence microscopy and indirect
immunofluorescence
For fluorescence microscopy, HeLa cells were
transfected with GFP-tagged LC3 using Lipofectamine
2000. Dot formation by GFP-LC3 was detected with a
fluorescence microscope (Olympus IX81) as previously
described [45]. Transfected cells with five or more puncta
were considered to have accumulated autophagosomes. A
total of 100 transfected cells were examined per well, in
triplicate, from three independent experiments.
For immunofluorescence microscopy, cells were
plated on coverslips (NEST, 801008) 24–48 h before
immunostaining. Cells were washed twice with ice-cold PBS
and were fixed in 4% paraformaldehyde (PFA) for 30 min,
permeabilized in 0.2% Triton X-100 for 15 min and
incubated for 60 min in 3% Bovine Serum Albumin (BSA).
Cells were then incubated with primary antibody overnight
followed by a secondary antibody in PBS containing 3%
BSA. Nuclei were stained with 5 μg/mL DAPI (Sigma) in
PBS. Images were acquired using a confocal microscope
(Leica TCS SP5 ×) with a 60 × oil objective. Images from
each experiment were acquired using the same exposure
time during the same imaging session. Quantification
of autophagic vacuoles was analyzed by calculating the
number of LC3 puncta from three fields containing more
than 5 randomly selected microscopy-captured images,
each comprising between 2 and 8 cells. Autophagosomes
were detected as RFP+GFP+ (yellow dot), while mature,
autolysosomal organelles were detected as RFP+GFP-

Plasmids, adenovirus and lentivirus
Myc-tagged Spred2 and deletion mutants (ΔEVH1,
ΔKBD and ΔSPR) were kindly provided by Prof. John
K Heath. Mutations for tryptophan 370/leucine 373 and
tyrosine 386/leucine 389 were mutated to Alanine in Spred2
and introduced by PCR-based site-directed mutagenesis. The
resulting construct was named Spred2-AA. The GFP-tagged
Spred2 was constructed per standard molecular cloning
procedures. FLAG-tagged p62 was kindly provided by Prof.
Haining Zhu. mRFP-GFP-tagged LC3 was kindly provided
by Yoshimori [43]. GFP-tagged LC3 was purchased from
Addgene. Adenoviruses expressing Myc-tagged Spred2
and Myc-tagged Spred2-ΔSPR and the control virus (AdVector) were previously described [8]. The AdEasy XL
adenoviral vector system (Stratagene) was used to generate
adenovirus-Myc-Spred2-AA. Primers used were as follows:
5′-GGGGTACCATGACCGAAGAAACACACC-3′ and
5′-GCCAAGCTTATGGTGATGGTGATGATG-3′. The
following lentiviral constructs were purchased from Santa
Cruz: p62 (SQSTM1) shRNA (sc-29679-V), ATG5 shRNA
(sc-41445-V), MAP LC3β shRNA (sc-43390-V) and noncoding shRNA (sc-108080). Lentiviral particles were used
to directly infect 293T, A549 and HeLa cells. Stable clones
were then selected using puromycin (Sigma). The selected
www.impactjournals.com/oncotarget
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(red-only dot) [46–48]. To examine the degree of overlap
of red (Myc-Spred2) and green (GFP-LC3) spots, analysis
of pixel co-localization was performed using the colocalization function of Image-Pro Plus software. The gain
and offset were lowered to prevent saturation in the brightest
signals. From each image three distinct areas (regions of
interest, ROIs) were sampled to correct for background.
Manders’ overlap coefﬁcient (R) was employed to evaluate
co-localization, and therefore could be used to determine
the co-localization of two signals. The values of Manders’
overlap co-efﬁcientare are in the range of 0 to 1.0. If the
image has an overlap coefficient of 1, it implies that 100%
of both selected channels overlap or co-localize. A value
of zero means that there are no overlapping pixels. It can
be used in any co-localization experiment. To assess the
reliability of this method, we applied the same procedure
to HeLa and COS7 cells for the co-localization of MycSpred2 and GFP-LC3. Quantification of the co-localization
was analyzed from three fields containing more than
5 randomly selected microscopy-captured images, each
of which comprised at least two cells. For each area an
average of coefﬁcients obtained from the examined ﬁeld
was calculated. The t-test was used to assess the results [49].

treatment groups and controls were performed using
Dunnett’s least significant difference (LSD) test. Statistical
significance between groups was calculated using the LSD
test in SPSS 17.0 software (SPSS Inc., Chicago, IL, USA).
A value of p < 0.05 was considered statistically significant.

Abbreviations
Spred, Sprouty-related protein with an EVH1
domain; EVH1, Ena/VASP homology 1; KBD, c-Kit
binding domain; SPR, Sprouty-related domain; LC3,
microtubule-associated protein 1 light chain 3; SQSTM1,
sequestosome 1; LIR, LC3-interacting region; Rapa,
rapamycin; CQ, chloroquine; BafA1, Bafilomycin A1;
siRNA, small interfering RNA; shRNA, short hairpin
RNA; IP, immunoprecipitation; IB, immunoblot.
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Flow cytometry analysis of apoptosis
Apoptosis was determined by ﬂow cytometric
analysis of membrane re-distribution of phosphatidylserine
using Annexin V and propidium iodide (PI) doublestaining technique. The cell population in the upper
right and lower right quadrants (Annexin V-positive/PIpositive and Annexin V-positive/PI-negative, respectively)
corresponds to apoptotic cells. The percentage of apoptotic
cells was determined in three independent experiments.
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